| |
Omega 3 (n = 19)
|
Control (n = 21)
|
Total (n = 40)
|
|---|
|
Male
|
14 (73.7%)
|
20 (95.2%)
|
34 (85.0%)
|
|
NZ European
|
13 (68.4%)
|
18 (85.7%)
|
31 (77.5%)
|
|
Age years)
|
63.3 (12.3)
|
59.3 (14.7)
|
61.2 (13.6)
|
|
Weight kg
|
89.0 (22.3)
|
91.4 (19.2)
|
88.8 (20.6)
|
|
BMI kg/m2
|
30.3 (6.5)
|
29.7 (5.2)
|
30.0 (5.8)
|
|
Hypertension
|
7 (36.8%)
|
9 (42.9%)
|
16 (40%)
|
|
Hyperlipidaemia
|
5 (26.3%)
|
5 (23.8%)
|
10 (25%)
|
|
Type 2 diabetes
|
3 (15.8%)
|
1 (4.8%)
|
5 (10%)
|
|
Ischaemic heart disease
|
0 (0)
|
2 (9.5%)
|
2 (5%)
|
|
Serum urate mmol/l
|
0.44 (0.08)
|
0.46 (0.08)
|
0.45 (0.08)
|
|
eGFR (ml/min/1.73m2)
|
68.5 (15.6)
|
69.7 (18.9)
|
69.1 (17.2)
|
|
Cholesterol (mmol/l)
|
5.4 (1.0)
|
5.2 (1.1)
|
5.3 (1.0)
|
|
Triglycerides (mmol/l)
|
2.1 (0.8)
|
2.4 (1.3)
|
2.3 (1.1)
|
|
HDL (mmol/l)
|
1.3 (0.3)
|
1.2 (0.3)
|
1.2 (0.3)
|
|
LDL (mmol/l)
|
3.1 (1.0)
|
3.0 (0.9)
|
3.0 (0.9)
|
|
Cholesterol (total/LDL)
|
4.3 (1.1)
|
4.5 (1.4)
|
4.4 (1.3)
|
|
Total red cell omega 3%
|
4.6 (1.2)
|
4.4 (0.9)
|
4.5 (1.0)
|
|
20:5n-3 (EPA)%
|
0.8 (0.3)
|
0.8 (0.3)
|
0.8 (0.3)
|
|
22:6n-3 (DHA)%
|
2.1 (0.5)
|
1.9 (0.4)
|
2.0 (0.5)
|
|
HbA1C (mmol/mol)
|
41.4 (16.2)
|
35.8 (11.1)
|
38.5 (13.9)
|
|
On allopurinol
|
8 (42.0%)
|
9 (43.0%)
|
17 (42.5%)
|
|
Serum Oxypurinol (µmol/l)
|
69.3 (38.4) (n = 8)
|
42.8 (28.6) (n = 9)
|
55.3 (35.2)
|
|
Tophi present
|
4 (21.1%)
|
3 (14.3)
|
7 (17.5%)
|
|
Flare prophylaxis
|
4 (21.1%)
|
2 (9.5%)
|
6 (15%)
|
- Data are presented as mean (SD) or n(%) unless otherwise stated
- NZ New Zealand, BMI body mass index, kg kilogram, eGFR estimated glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, EPA eicosapentaenoic acid and DHA docosahexaenoic acid
